Integrin-linked Kinase And Protein Kinase B Expression Increases With Ovarian Tumour Grade And Its Clinical Significance

Bavkground:Intergin-linked kinase (ILK) is a recently identified protein serine/threonine kinase. ILK participates in regulating signal conduction via integrin and growth factors. ILK has been demonstrated to possess a number of oncogrnic properties. ILK activates protein kinase B (PKB) by phosphorylate it on ser473 .PKB is a major downstream target of ILK. Mounting evidence suggests that PKB perturbations play an important role in human malignancy. The ILK and PKB appears to play a prominent role in several processes thought to be critical in tumorogenesis, including aberrant cell proliferation, inhibition of programmed cell death,tedomerase activation and promotion of angiogenesis and tumor cell invasiveness.Objective: To demonstrate the relative expression of integrin-linked kinase (ILK) and protein kinase B (PKB)in normal, benign,lowgrade,and highgrade ( borderline, grade1/2,and grade3) ovarian tumour in order to study expression and clinical meaning of ILK and PKB in epithelial ovarian cancer.Methods: 210 specimens including normals (n=30), benign (n=30) (17 serious,13 mucinous), borderline(n=44)(19 serious,25 mucinous),carcinoma (n=106) ( 59 serious, 19 mucinous,17endometrioid , 11 clear cell carcinoma) were evaluated by immunohistochemistry staining (SP methods) .The difference of ILK and PKB expression was determined by chi-squaretest using the SPSS 10.0 statistical package.Results: 1. No immunoreactive ILK was observed in normal ovaries(n=30) or in ten of seventeen benign ovarian serous cystadenomas.The other seven benign serous cystadenomas showed weak staining. In seven of thirteen benign ovarian mucinous howed weak staining, the other six benign ovarian mucinous showed Moderate. Moderate expression of ILK protein was detected in 68.2% of borderline ovarian tumours, strong expression was detected in 31.8%. Moderate expression of ILK protein was detected in 34.0% of ovarian cancers, strong expression was detected in 66.0%.2. No immunoreactive pPKB was observed in normal ovaries(n=30) or in thirteen of seventeen benign ovarian serous cystadenomas.The other four benign serous cystadenomas showed weak staining. In nine of thirteen benign ovarian mucinous howed weak staining, the other four benign ovarian mucinous showed Moderate. Moderate expression of pPKB protein was detected in 75.0% of borderline ovarian tumours, strong expression was detected in 25.0%. Moderate expression of pPKB protein was detected in 38.7% of ovarian cancers, strong expression was detected in 61.3%.3. The expression ofILK and pPKB protein in ovarian cancers was much higher than borderline ovarian tumours, the expression of ILK and pPKB protein in borderline ovarian tumours was much higher than benign tumours. The expression of ILK and pPKB protein was not correlated to age, Histological types. In ovarian cancer, there was significant differenceamong clinical stageâ… -â…¡VSâ…¢-â…£(P<0.01), and was associated with low grade, presence of ascites and lymph node metastasis (P<0.01).4. The result of correlation analysis between of ILK and pPKB protein expression was dramarily significant(r=0.739,P<0.01).Conclusion: The abnormal expression of ILK and pPKB is significiantly associated to the ovarian cancer, between of ILK and pPKB protein expression was dramarily significant, the overexpression of ILK and pPKB protein may be the potient biomarker for ovarian cancer, ILK and pPKB may serve as a useful marker of the biological behavior of ovarian tumors ,and can provide useful information for prognosis of ovarian tumor patients.